Skip to main content Back to Top
Advertisement

11/12/2019

Octreotide Injection

Products Affected - Description

    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0455-05
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01

Reason for the Shortage

    • Fresenius Kabi had octreotide injection on back order due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional refuses to provide availability updates.
    • Sagent has octreotide on shortage due to increased demand.
    • Sun Pharma is not currently marketing octreotide.
    • Teva did not provide a reason for the shortage.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.

Available Products

    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-10
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0454-05
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
    • Octreotide Acetate injection, Teva, 100 mcg/mL, 1 mL vial, 25 count, NDC 00703-3311-04
    • Octreotide Acetate injection, Teva, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00703-3343-01
    • Octreotide Acetate injection, Teva, 200 mcg/mL, 5 mL vial, 1 count, NDC 00703-3333-01
    • Octreotide Acetate injection, Teva, 50 mcg/mL, 1 mL vial, 25 count, NDC 00703-3301-04
    • Octreotide Acetate injection, Teva, 500 mcg/mL, 1 mL vial, 25 count, NDC 00703-3321-04

Estimated Resupply Dates

    • Hikma has octreotide 100 mcg/mL 1 mL vials and 500 mcg/mL 1 mL vials on back order and the company estimates a release date of early-April 2020.
    • Sagent has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date in November 2019. There are short-dated 1,000 mcg/mL 5 mL vials available with an expiration date of February 2020.

Updated

Updated November 12, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins